Matinas Biopharma Holdings Inc Stock News
$0.179
-0.0026 (-1.43%)
At Close: Apr 26, 2024
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q1 2020 Results - Earnings Call Transcript
02:45am, Tuesday, 12'th May 2020
Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Peter Vozzo - Investor Relations J
Matinas Biopharma Holdings Inc (MTNB) Reports Q1 Loss, Misses Revenue Estimates
11:45pm, Monday, 11'th May 2020
Matinas Biopharma Holdings Inc (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for t
Matinas BioPharma Reports First Quarter 2020 Financial Results and Operational Highlights
08:05pm, Monday, 11'th May 2020
– ENHANCE-IT study of MAT9001 against Vascepa® set to resume in June 2020 – – EnACT study of MAT2203 in cryptococcal meningitis expected to resume in June 2020 – – Management.
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2020 Financial and Operational Results on May 11, 2020
11:00am, Monday, 04'th May 2020
Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conferenc
Matinas BioPharma to Participate in Panel Discussion During Maxim Group Infectious Disease Virtual Conference
11:00am, Tuesday, 28'th Apr 2020
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a panel discussion, as well as host investor mee
Edited Transcript of MTNB earnings conference call or presentation 9-Mar-20 12:00pm GMT
09:10pm, Tuesday, 07'th Apr 2020
Q4 2019 Matinas BioPharma Holdings Inc Earnings Call
Investors Who Bought Matinas BioPharma Holdings (NYSEMKT:MTNB) Shares Three Years Ago Are Now Down 81%
02:10pm, Thursday, 02'nd Apr 2020
Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So take a moment to...
Fly Intel: Pre-market Movers CCO;SQNS;NBL;PEI;CAG;RH;SNDL;DLTR;MTNB;CCL;TWLO
01:25pm, Tuesday, 31'st Mar 2020
Fly Intel: Pre-market Movers CCO SQNS NBL PEI CAG RH SNDL DLTR MTNB CCL TWLO
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States District Court decision to invalidate patents related to Ama
Fly Intel: Wall Street's top stories at midday TGNA;APO;SOGO;LYV;MTNB;MGIC;OXY;XEC;MRO;APA;FANG;CAT;JPM;DOW;CVX;XOM
04:14pm, Monday, 09'th Mar 2020
Fly Intel: Wall Street's top stories at midday TGNA APO SOGO LYV MTNB MGIC OXY XEC MRO APA FANG CAT JPM DOW CVX XOM
Fly Intel: Pre-market Movers KALA;DHT;SOGO;SOHU;MTNB;MGIC;LYV;BP;CVX;XOM;COP;RDS.A;RDS.B;TOT;OXY;SLB;RIG
01:39pm, Monday, 09'th Mar 2020
Fly Intel: Pre-market Movers KALA DHT SOGO SOHU MTNB MGIC LYV BP CVX XOM COP RDS.A RDS.B TOT OXY SLB RIG
Matinas BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
10:30am, Monday, 09'th Mar 2020
Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020 Initiated efficacy phase of NIH-funded EnACT study of MAT2203 in cryptococcal meningitis.
Matinas Biopharma Holdings, Inc. to Host Earnings Call
10:00am, Monday, 09'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 9, 2020 / Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on Marc
Fly Intel: Wall Street's top stories for Monday DOW CVX XOM JPM CAT FANG APA MRO XEC OXY AON WLTW TWTR INO INTU TGNA SOGO LYV MTNB MGIC
